Citations 1
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Spratt, Daniel E., Srinivas, Sandy, Ahmed, Bilawal, An, Yi , Bitting, Rhonda, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, T. B., Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, S, Karnes, R. Jeffrey, Kishan, Amar U., Kuettel, Michael, Lang, J., Lee, Daniel, Lotan, Tamara, McDonald, Andrew, Morgan, Todd M. , Pessoa, Rodrigo, ROACH, M, Robin, Tyler, Rosenfeld, Stan, Scarpato, Kristen R., Seibert, Tyler, Shabsigh, Ahmad, Szmulewitz, Russell, Tward, Jonathan, Valicenti, Richard, VanderWeele, David, Wong, J.K. , Kovách, E, Freedman-Cass, Deborah, Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Bitting, Rhonda L. , Chapin, Brian F. , Cheng, Heather H., Cho, Steve Y. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, Jeff , Gupta, Shilpa , Ippolito, Joseph E. , Kishan, Amar U. , McDonald, Andrew M. , Rais‐Bahrami, Soroush , Roach, Mack , Scarpato, Kristen R., Shabsigh, Ahmad , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , Valicenti, Richard K., VanderWeele, David James , Freedman-Cass, Deborah A.
Journal of the National Comprehensive Cancer Network | May 14, 2026 | Volume: 24 | Issue: 5 | Pages: 140-149
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel’s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.